Dokument
Biogen Idec announces multiple sclerosis franchise and pipeline
2008-04-15 08:24Biogen Idec today announced that 17 company-sponsored plenary sessions, platform presentations, and poster presentations will be presented during the 60th Annual Meeting of the American Academy of Neurology. These presentations will cover four compounds that are marketed or currently in development by Biogen Idec and its partners for the treatment of multiple sclerosis (MS).
Lägg till kommentarKommentaren sparades
Innan den publiceras måste den godkännas av BiogenIdec Sweden AB.